by The fecal calprotectin test market is estimated to be valued at US$ 140.6 Mn in 2023 and is expected to exhibit a CAGR of 12.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Fecal calprotectin testing is a non-invasive medical test used to help diagnose and monitor inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn’s disease. Calprotectin is a protein found in the neutrophils of the immune system. When the intestine is inflamed as in IBD, calprotectin leaks into the stool. The level of calprotectin in the stool corresponds to the amount of gut inflammation. Fecal calprotectin tests help physicians monitor disease activity and response to treatment in IBD patients.
Market Dynamics:
The growth of the fecal calprotectin test market is driven by the increasing incidence and prevalence rates of IBD worldwide. According to the Crohn’s and Colitis Foundation of America, it is estimated that approximately 1.6 million Americans are affected by IBD. A rising geriatric population is also expected to fuel the demand for fecal calprotectin tests as the risk of IBD increases with age. Furthermore, growing awareness regarding new diagnostic methods for IBD is encouraging more patients and physicians to adopt fecal calprotectin testing for effective disease management. Product launches and approvals are also expected to support market growth over the forecast period. For instance, in 2019, BÜHLMANN Laboratories received FDA approval for its fecal calprotectin ELISA tests to aid in the diagnosis of IBD.
Segment Analysis
The fecal calprotectin test market is dominating by point-of-care testing (POCT) segment due to rising preference for convenient home sample collection. POCT eliminates the need for patients to visit diagnostic laboratories for testing as it provides onsite rapid results within 30 minutes using stool samples.
PEST Analysis
Political: Regulations supporting diagnosis of gastrointestinal disorders will boost the market growth. For instance, In U.S., Affordable Care Act provided health insurance to millions resulting in increased diagnosis rates.
Economic: Rising disposable incomes in developing nations led to increased healthcare spending which is a key factor supporting the market size.
Social: Growing awareness among patients regarding gastrointestinal disease diagnosis is a major driver for early testing.
Technological: Developments in lateral flow assays resulted in compact, easy-to-use POCT devices with high sensitivity and specificity expanding outreach in remote locations.
Key Takeaways
The Global Fecal Calprotectin Test Market Size is expected to witness high growth, exhibiting a CAGR of 12.3% over the forecast period, due to increasing diagnosis rates of gastrointestinal disorders like inflammatory bowel disease.
Regionally, North America accounted for the largest market share in 2023 primarily due to supportive regulatory scenario and presence of key players. However, Asia Pacific is anticipated to grow at fastest pace owing to rising health expenditures and growing patient awareness in densely populated countries like China and India.
Key players operating in the fecal calprotectin test market are Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbexa Limited, Bioserv Diagnostics Gmbh, Epitope Diagnostics, Inc., LifeSpan BioSciences, Inc., RayBiotech, Inc., ALPCO. These players are focusing on new product launches and geographical expansion strategies to gain competitive advantage in the market.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc.
